Serious side effects, while rare, include pancreatitis, gallbladder issues, hypoglycemia, dehydration, and in extreme cases organ dysfunctionespecially when misused or combined with unregulated compounds
Evidence of past weight loss attempts: Some plans require proof of previous diet and exercise attempts before approving GLP-1s
The mean reduction in body weight from baseline to week 104 was significantly higher in the semaglutide group (n = 152) compared to the placebo group (n = 152), with an estimated treatment difference of -12.6 percentage points (95% confidence interval: -15.3 to -9.8
Infliximab for GVHD therapy in children
It can be used by adults with a body mass index (BMI) greater than or equal to 30 mg/kg alone or 27 mg/kg with at least one weight-related condition (e.g., high blood pressure, high cholesterol, Type 2 diabetes)